Aptevo Therapeutics Inc
For the period ended Dec 31, 2023. Filed Mar 5, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 5, 2024
APVO$1.13-8.9%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations
(in thousands, except share and per share amounts)
| For the Year Ended December 31, | |||
|---|---|---|---|
| 2023 · 2022 | |||
| Royalty revenue | $ | — | $3,114 |
| Operating expenses: | |||
| Research and development | (17,107) | (17,882) | |
| General and administrative | (11,771) | (13,873) | |
| Loss from operations | (28,878) | (28,641) | |
| Other income (expense): | |||
| Other income (expense) from continuing operations, net | 578 | (4,027) | |
| Gain related to sale of non-financial asset | 9,650 | — | |
| Gain on extinguishment of liability related to sale of royalties | — | 37,182 | |
| Milestone income related to sale of royalties | — | 2,500 | |
| Net (loss) income from continuing operations | (18,650) | 7,014 | |
| Discontinued operations: | |||
| Income from discontinued operations | 1,239 | 1,013 | |
| Net (loss) income | $ | (17,411) | $8,027 |
| Net (loss) income per share: | |||
| Basic | $ | (1.42) | $1.57 |
| Diluted | $ | (1.42) | $1.57 |
| Shares used in calculation: | |||
| Basic | 12,234,661 | 5,100,310 | |
| Diluted | 12,234,661 | 5,102,914 | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.